课题基金 / 基金详情

项目摘要

项目成果

melody c carter的其他基金

相似基金

相关文献

中文摘要
翻译
在我们正在进行的研究中,我们发现血清胰蛋白酶似乎反映了疾病的程度,并作为疾病消退和进展的生物标志物。我们也在增加有一个以上受影响家庭成员的家庭的登记,以便调查遗传关联。
英文摘要
In our on-going studies, we have found that serum tryptase appears to reflect extent of disease and to serve as a biomarker of both disease regression and progression. We are also increasing our enrollment of families with more than one affected family member in order to investigate genetic associations. We are also documenting bone marrow biopsy findings that may similarly be used to predict disease progression and may lead the way to an improved classification of pediatric onset mastocytosis. Activating mutations in codon D816 of the tyrosine kinase receptor, KIT, are found in the majority of patients with systemic mastocytosis. In a collaboration with Dr. Takemoto and his research group, we found that the transcription factor, microphthalmia-associated transcription factor (MITF), is highly expressed in bone marrow biopsies from patients with systemic mastocytosis and activating c-KIT mutations and that KIT signaling markedly up-regulates MITF protein. MITF mRNA levels did not change significantly with KIT signaling which suggested posttranscriptional regulation. An array screen from mast cells identified miR-539 and miR-381 as being down-regulated by KIT signaling and that they repressed MITF expression through conserved miRNA binding sites in the MITF 3'-untranslated region. Forced expression of these miRNAs suppressed MITF protein and inhibited colony-forming capacity of mastocytosis cell lines, supporting the conclusion that a novel regulatory pathway exists between 2 critical mast cell factors, KIT and MITF which is mediated by miRNAs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pediatric Inflammatory Diseases of the Respiratory Tract
The Natural History of Pediatric Onset Cutaneous and Systemic Mastocytosis
The Natural History of Pediatric Onset Cutaneous and Systemic Mastocytosis
Pathogenesis and Treatment of Anaphylaxis
海外基金